VEGFA and age-related macular degeneration: The involvement of VEGF in AMD has led to the Food and Drug Administration approval of two intraocular anti-VEGF drugs, pegaptanib sodium (Macugen, OSI/Eyetech Pharmaceuticals, NY) [12], an aptamer which was reported to inhibits only VEGF165, and ranibizumab (Lucentis, Genentech) [13], a Fab fragment of the humanized monoclonal VEGF antibody bevacizumab (Avastin, Genentech) which neutralizes all VEGF isoforms.